Subscribe To
Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update
Completed reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2022 with approximately $194.6 million in cash and cash equivalents Initiated two Phase 2 trials, AURORA and BEACON, for bitopertin in erythropoietic protoporphyria (EPP); initial BEACON data to be shared 1H 2023 and topline AURORA data expected by end of 2023 Completed […] The post Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update appeared first on ForexTV...
Read More
Posted: Mar 31 2023, 11:00
Author Name: forextv
Views: 110128